



an Open Access Journal by MDPI

## Dopamine and Serotonin Receptors: Selective or Multitarget Ligands for the Treatment of Central Nervous System Diseases

Guest Editors:

**Dr. Fabio Del Bello**

Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, 62032 Camerino, Italy

**Dr. Wilma Quaglia**

Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, 62032 Camerino, Italy

Deadline for manuscript submissions:

**25 November 2024**

### Message from the Guest Editors

Dear Colleagues,

Dopamine and serotonin neurotransmitter pathways play important roles in regulating several physiological functions in the central nervous system and are altered in numerous diseases, including psychiatric and neurodegenerative disorders. An efficacious treatment strategy involves the discovery and development of ligands selectively targeting dopamine or serotonin receptor subtypes, with limited side effects (“magic bullets”).

However, the multitarget or “magic shotgun” approach, combining dopamine and serotonin receptor systems, might produce improved results in the treatment of polyfactorial pathologies. Indeed, with respect to combined therapies, multitarget drugs may offer clear advantages, including reduced risk of drug interactions, more predictive pharmacokinetics, and better patient compliance.

We invited you to submit original or review articles dealing with the discovery and/or development of subtype selective or multitarget ligands targeting dopamine and/or serotonin receptors potentially useful for the treatment of central nervous system diseases.

Dr. Fabio Del Bello  
Dr. Wilma Quaglia  
Guest Editors



[mdpi.com/si/180896](https://mdpi.com/si/180896)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)